Contineum Therapeutics, Inc. (CTNM)

Contineum Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022
Revenue	50	0
Gross Profit	50	0
Selling, General & Admin	6.32	5.83
Research & Development	27.6	16.89
Operating Expenses	33.92	22.72
Operating Income	16.08	-22.72
Interest Expense / Income	0.21	0.39
Other Expense / Income	12.27	1.15
Pretax Income	3.6	-24.25
Income Tax	0.45	0
Net Income	3.15	-24.25
Shares Outstanding (Basic)	2	2
Shares Outstanding (Diluted)	3	2
Shares Change	51.38%	-
EPS (Basic)	1.36	-10.81
EPS (Diluted)	0.08	-10.81
Free Cash Flow	18.94	-20.24
Free Cash Flow Per Share	8.20	-9.02
Gross Margin	100.00%	-
Operating Margin	32.15%	-
Profit Margin	6.29%	-
Free Cash Flow Margin	37.87%	-
Effective Tax Rate	12.51%	-
EBITDA	4.96	-22.61
EBITDA Margin	9.93%	-
Depreciation & Amortization	1.16	1.26
EBIT	3.8	-23.87
EBIT Margin	7.61%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).